Abstract: Medical articles include a substrate with a layer of a siloxane-based gel adhesive composition. The gel adhesive composition includes a crosslinked polymeric siloxane matrix, and an extractable polymeric fluid with a weight average molecular weight greater than 275,000 grams/mole. The extractable polymeric fluid is 26-80 weight % of the gel adhesive composition. The gel adhesive composition may also include a siloxane tackifying resin.

Abstract: Silicone-polyether copolymers, adhesives and medical articles comprising same, and methods of making same. The silicone-polyether copolymer composition can include a backbone composition having a first (silicone) segment and a second (polyether) segment connected randomly via at least one of an oxamide linkage and a urea linkage. The method of making the silicone-polyether copolymer composition can include combining: a) a first (silicone) precursor; b) a second (polyether) precursor; and c) at least one of a diisocyanate and an oxalate compound.

Abstract: Dithienylpyrrole compounds, compositions containing dithienylpyrrole polymers, and methods for making the compounds and compositions are disclosed herein. The compositions containing dithienylpyrrole polymers, can for example, be used as conducting polymers in biosensors for detecting analytes in a sample.

Abstract: An graphene composites have reduced graphene oxide and a layered double-hydroxide distributed on the reduced graphene oxide. The composites may also include nanopores formed within the reduced graphene oxide and micropores that may be formed by the reduced graphene oxide. The composites may exhibit superior electrical and/or absorbent properties. Capacitor devices and electrodes containing the composites are also disclosed, as well as methods and systems configured to make and use the composites.

Abstract: Silicone-polyether copolymers, adhesives and medical articles comprising same, and methods of making same. The silicone-polyether copolymer composition can include a backbone composition having a first (silicone) segment and a second (polyether) segment connected randomly via at least one of an oxamide linkage and a urea linkage. The method of making the silicone-polyether copolymer composition can include combining: a) a first (silicone) precursor; b) a second (polyether) precursor; and c) at least one of a diisocyanate and an oxalate compound.

Abstract: Dithienylpyrrole compounds, compositions containing dithienylpyrrole polymers, and methods for making the compounds and compositions are disclosed herein. The compositions containing dithienylpyrrole polymers, can for example, be used as conducting polymers in biosensors for detecting analytes in a sample.

Abstract: An graphene composites have reduced graphene oxide and a layered double-hydroxide distributed on the reduced graphene oxide. The composites may also include nanopores formed within the reduced graphene oxide and micropores that may be formed by the reduced graphene oxide. The composites may exhibit superior electrical and/or absorbent properties. Capacitor devices and electrodes containing the composites are also disclosed, as well as methods and systems configured to make and use the composites.

Abstract: The present invention discloses a use of N-acetyl-D-glucosamine in the manufacture of a medicament for treatment of urogenital tract infection. N-acetyl-D-glucosamine exhibits a function of suppressing the transplantation of exotic microorganisms and promoting the repair of topical skin tissue, and the formulation comprising it as a main active component is used for the prevention and treatment of urogenital tract infection and has advantages such as notable therapeutic effect, easy preparation, non-irritation, non-contamination, etc.

Abstract: The present invention is directed to the use of N-acetyl-D-glucosamine to treat organ lesions caused by toxicants and drugs. The present invention is also directed to a method for treating organ lesions caused by toxicant comprising administering to a patient suffering from organ lesions a pharmaceutical composition comprising N-acetyl-D-glucosamine or a pharmaceutically acceptable salt thereof.

Abstract: The present invention has disclosed a use of N-acetyl-D-glucosamine in the preparation of a medicament for treating tumors and metastatic diseases. N-acetyl-D-glucosamine is able to regulate cellular membrane, constitute a stable structural component of cellular membrane, participate metabolism process of tumor cells, and stop energy supply to cause the death of tumor cells. As a drug for adjustment therapy, it showed significant effects in the laboratory researches, animal tests and human body trials.

Abstract: The present invention has disclosed a use of N-acetyl-D-glucosamine in the preparation of a medicament for regulating microecological balance of mucocutaneous membrane. N-acetyl-D-glucosamine has functions of promoting bacteria and cellular redistribution and against allochthonous flora colonization. Preparations comprising N-acetyl-D-glucosamine as main active substance are able to be used for regulating microecological balance of mucocutaneous membrane, and have advantages of significant therapeutic effects, simple manufacture, nonirritant, non-pollution, etc.

Abstract: The use of the combination of N-acetyl-D-glucosamine and antibiotics for the preparation of antibacterial drugs is disclosed. In the therapies of infections with antibiotics, the pathogens may be changed into slender shaped forms called cryptic growth cells (CGCs), CGCs can colonize and thereby physiological drug resistance arises. In the meantime, normal bacteria colonies in the body may be also changed into CGCs upon administration of antibiotics. These changes result in complications after the therapies, such as disorder of bacteria colonies in the body, disorder of GI functions and other chronic diseases. The combination of antibiotics and N-acetyl-D-aminoglycosamine can prevent of CGC, and the complications after antibiotics therapy.

Abstract: The present invention relates to a use of N-acetyl-D-glucosamine in the manufacture of a medicament for treating non-specific inflammations caused by physical/chemical factors and controlling symptoms thereof. A preparation comprising N-acetyl-D-glucosamine as main active component for treating non-specific inflammations caused by physical/chemical factors exhibits merits of significant therapeutical effects and simple manufacture and has no side effect.

Abstract: The present invention discloses a method for treating local lesions or systematic symptoms caused by autoimmune reactions, a use of N-acetyl-D-glucosamine for treating local lesions or systematic symptoms caused by autoimmune reactions, and a use of N-acetyl-D-glucosamine in the manufacture of a medicament for treating local lesions or systematic symptoms caused by autoimmune reactions.

Abstract: The present invention discloses a use of N-acetyl-D-glucosamine or pharmaceutically acceptable salts thereof in the manufacture of a medicament for treating local lesions or systematic symptoms caused by infections of virus or bacteria. A parenteral preparation comprising N-acetyl-D-glucosamine or pharmaceutically acceptable salts thereof as active component is capable of controlling systematic toxic symptoms caused by infections of virus and bacteria and local and systematic lesions caused by endotoxins and exotoxins, and exhibits an excellence rate of 90%.

Abstract: The present invention discloses a use of N-acetyl-D-glucosamine in the manufacture of a medicament for treating organ lesions caused by toxicants and drugs. A preparation comprising N-acetyl-D-glucosamine as main active component for treating organ lesions caused by toxicants and drugs exhibits merits of a directive action mechanism, significant therapeutical effects and simple manufacture and has no side effect.

Abstract: In one aspect, the invention provides a fluorochemical composition comprising a mixture of: a fluorochemical selected from the formula: wherein RF is a fluorinated group having the formula: Rf—W—, wherein Rf is a perfluoroalkyl or perfluoropolyether group and W is a divalent linking group; PI is a monovalent pendant organic moiety comprising benzophenone, substituted benzophenone, acetophenone, or substituted acetophenone groups; R is H, CH3, or F; Rh is lower alkyl selected from the group consisting of linear or branched alkyl groups having from 1 to about 8 carbon atoms, cycloalky containing alkyl groups having from 4 to about 8 carbon atoms, and cycloalkyl groups having from 3 to about 8 carbon atoms, all optionally containing catenated O or N atoms; m is at least 2; n is at least 1; q is zero or greater; and a hydrofluoroether.

Abstract: The present invention has disclosed a use of N-acetyl-D-glucosamine in the manufacture of a medicament for resisting cardiac and cerebral ischemia and oxygen-deficiency. N-acetyl-D-glucosamine can obviously prolong the survival time of the experimental animal under the condition of cerebral ischemia and oxygen-deficiency at normal pressure, can decrease cerebral edema degree and other symptoms of the nerve behavior caused by cerebral ischemia and re-infusion.

Abstract: The present invention discloses a use of N-acetyl-D-glucosamine in the manufacture of a medicament for treatment of urogenital tract infection. N-acetyl-D-glucosamine exhibits a function of suppressing the transplantation of exotic microorganisms and promoting the repair of topical skin tissue, and the formulation comprising it as a main active component is used for the prevention and treatment of urogenital tract infection and has advantages such as notable therapeutic effect, easy preparation, non-irritation, non-contamination, etc.

Abstract: The present invention has disclosed a use of N-acetyl-D-glucosamine in the manufacture of a medicament for inhibiting the side effect of radio-chemical therapy, the medicament with N-acetyl-D-glucosamine as main active component can be used to inhibit the side effect of radio-chemical therapy of cancer patients, with an effective rate up to 85%.